Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Duoduo Pharmaceutical Co., Ltd. (hereinafter referred to as Duoduo Pharmaceutical), a subsidiary of the company, recently received the “Notice of Acceptance” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration), and the marketing license application for calcium hydroxybenzenesulfonate capsules (specification: 0.5g) was accepted.

Calcium oxybenzenesulfonate capsules are indicated for: 1. Treatment of microangiopathy: diabetic microangiopathy - retinopathy and glomerulosclerosis (Giller-Weiss syndrome); microvascular damage - accompanied by increased capillary fragility and permeability, capillariasis, cyanosis of hands and feet. 2. Adjuvant treatment for chronic venous insufficiency (varicose vein syndrome) and its sequelae (post-embolic syndrome, leg ulcers, purpura dermatitis, etc.).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.